wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38404422-98AC4E5D-1ADD-45EC-9A22-9F1FDB022D45
Q38404422-98AC4E5D-1ADD-45EC-9A22-9F1FDB022D45
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-98AC4E5D-1ADD-45EC-9A22-9F1FDB022D45
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
P2860
Q38404422-98AC4E5D-1ADD-45EC-9A22-9F1FDB022D45
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-98AC4E5D-1ADD-45EC-9A22-9F1FDB022D45
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
38c4135fe57d9f81540a31d707b3606ba694db31
P2860
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.